GLP-1受体激动剂治疗阻塞性睡眠呼吸暂停的Meta分析
本研究系统检索并汇总了5项随机对照试验(948例患者),评估GLP-1受体激动剂(利拉鲁肽和替尔泊肽)对比对照组的疗效。结果显示GLP-1受体激动剂显著降低呼吸暂停低通气指数(Δ=-12.4次/小时),且不依赖于持续气道正压通气(CPAP)的使用,同时带来体重、腰围和血压的改善,但胃肠道不良事件更常见。
要点
- GLP-1受体激动剂降低AHI 12.4次/小时,独立于CPAP使用。
- 体重降低12.5%,腰围减少3.3 cm,收缩压和舒张压分别降低4.5 mmHg和1.30 mmHg。
- 胃肠道不良事件在GLP-1受体激动剂组更常见。
核心结论
- GLP-1受体激动剂对阻塞性睡眠呼吸暂停严重程度产生有临床意义的改善,且不依赖于CPAP使用。
研究设计与样本
- 纳入5项评估GLP-1受体激动剂(利拉鲁肽和替尔泊肽)治疗阻塞性睡眠呼吸暂停的随机对照试验,共948例患者(GLP-1组479例,对照组469例)。
- 主要结局为呼吸暂停低通气指数变化,并按CPAP使用分层分析。
主要发现
- 收缩压和舒张压分别降低4.5 mmHg(95%CI:-6.4至-2.7)和1.30 mmHg(95%CI:-2.59至-0.01)。
- 胃肠道不良事件在GLP-1受体激动剂组更常见。
关键数值与推荐
- 纳入标准为评估GLP-1受体激动剂(利拉鲁肽和替尔泊肽)治疗阻塞性睡眠呼吸暂停的随机对照试验。
- 主要结局指标为呼吸暂停低通气指数的变化。
- 数据按CPAP使用与否进行分层,效应量以均数差(Δ)及95%CI汇总。
临床怎么用
- 对于阻塞性睡眠呼吸暂停患者,GLP-1受体激动剂可考虑作为改善疾病严重程度的药物治疗选择,无论是否使用CPAP。
- 使用GLP-1受体激动剂时需关注胃肠道不良事件。
- GLP-1受体激动剂可同时带来体重、腰围和血压的改善,可能对合并肥胖和高血压的OSA患者有益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate glucagon-like peptide 1 receptor agonists for obstructive sleep apnea compared with controls. DATA SOURCES: CINAHL, Cochrane Library, PubMed, and Scopus. REVIEW METHODS: A PRISMA-compliant search was conducted from database inception through October 2025. Randomized controlled trials evaluating glucagon-like peptide 1 receptor agonist use (liraglutide and tirzepatide) for obstructive sleep apnea were included. The primary outcome was the change in apnea-hypopnea index. Data on apnea-hypopnea index, body weight, waist circumference, blood pressure, inflammatory markers, and adverse events were extracted and stratified by continuous positive airway pressure use. Outcomes were summarized as mean differences (Δ) with 95% confidence intervals (CI). Risk of bias was assessed using the Cochrane Risk of Bias 2 tool. RESULTS: Of 3,836 articles screened, five studies met the inclusion criteria, comprising 948 patients (479 GLP-1; 469 control). Glucagon-like peptide 1 receptor agonists reduced apnea-hypopnea index by 12.4 events/hour more than controls (95% CI: -17.2 to -7.7; P < .00001), independent of continuous positive airway pressure use. Glucagon-like peptide 1 receptor agonists produced greater weight loss (Δ: -12.5%; 95% CI: -22.0% to -3.0%; P = .01) and reduced waist circumference (Δ: -3.3 cm; 95% CI: -4.4 to -3.2; P < .00001). Systolic and diastolic blood pressure decreased by 4.5 mmHg (95% CI: -6.4 to -2.7) and 1.30 mmHg (95% CI: -2.59 to -0.01), respectively. Gastrointestinal adverse events were more common with glucagon-like peptide 1 receptor agonists. CONCLUSION: Glucagon-like peptide 1 receptor agonists produced clinically meaningful improvements in obstructive sleep apnea severity, independent of continuous positive airway pressure use.
引用
- Loblundo C, Gao SY, Nguyen SA, et al. Glucagon-Like Peptide-1 Receptor Agonists for Obstructive Sleep Apnea With and Without Continuous Positive Airway Pressure. Otolaryngol Head Neck Surg. 2026. PMID: 42611692. doi:10.1002/ohn.70407
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。